GLI1 and neoplasm: Oncogenic pathways (KRAS/BRAF in colon cancer) circumvent the canonical HH-GLI axis by converging on and further driving GLI to a higher activating state in tumor cells, promoting cellular proliferation, tumor progression and survival [8, 15, 19, 40-42, 43, 44].